Search

Your search keyword '"OKANOUE, T."' showing total 691 results
Start Over Author "OKANOUE, T."
691 results on '"OKANOUE, T."'

1. Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis

Author

Seko Y, Nishikawa T, Umemura A, Yamaguchi K, Moriguchi M, Yasui K, Kimura M, Iijima H, Hashimoto T, Sumida Y, Okanoue T, and Itoh Y

Subjects
canagliflozin, Japanese, NASH, fibrosis stages, SGLT2 inhibitor, type 2 diabetes mellitus, Specialties of internal medicine, RC581-951
Abstract

Yuya Seko,1 Taichiro Nishikawa,1 Atsushi Umemura,1 Kanji Yamaguchi,1 Michihisa Moriguchi,1 Kohichiroh Yasui,1 Mayumi Kimura,2 Hiroaki Iijima,3 Toshio Hashimoto,3 Yoshio Sumida,4 Takeshi Okanoue,5 Yoshito Itoh1 1Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan; 2Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Osaka, Japan; 3Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan; 4Division of Hepatology and Pancreatology, Department of Internal Medicine, Aichi Medical University, Aichi, Japan; 5Department of Gastroenterology and Hepatology, Saiseikai Suita Hospital, Osaka, Japan Aim: Nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH), is known to be associated with type 2 diabetes mellitus (T2DM) in high rate. The improvement in hepatic function due to sodium-glucose co-transporter 2 (SGLT2) inhibitors has been reported in T2DM patients with and without NAFLD. However, only a few studies have attempted to evaluate the role of SGLT2 inhibitors in T2DM patients with biopsy-proven NASH, and no detailed prospective studies including the individual hepatic fibrosis stage have been reported. Therefore, we investigated the effect of canagliflozin on hepatic function in T2DM patients with biopsy-confirmed NASH. Methods: T2DM patients with NASH (hepatic fibrosis stage 1–3 confirmed via liver biopsy, n=10) were enrolled and received canagliflozin (100 mg) once a day for 12 weeks. The primary end point was change in serum alanine aminotransferase (ALT) levels from baseline to week 12. Secondary end points were liver function/fibrosis markers, metabolic parameters, and safety. Results: The change in ALT from baseline to week 12 was -23.9 U/L (95% CI –48.1 to 0.3, P=0.0526). Significant improvements in several hepatic function/fibrosis markers, such as aspartate aminotransferase, fibrosis-4 index, and FM-fibro index, and metabolic parameters including hemoglobin A1c and body weight were found. No serious or liver-related adverse events were reported. Regarding individual patients, different trends in ALT-lowering effects between stage 1 and stage 2/3 subjects were observed; the degree of ALT-lowering effect tended to be greater in the stage 1 group than in the stage 2/3 group. Conclusion: Our results suggest that canagliflozin is effective and well-tolerated in patients with T2DM and NASH. Canagliflozin may be useful for the treatment of T2DM patients with NASH, especially those in early stages of NASH. Keywords: canagliflozin, Japanese, NASH, fibrosis stages, SGLT2 inhibitor, type 2 diabetes mellitus

Published
2018

2. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD : an individual patient data meta-analysis

Author

Mozes, F. E., Lee, J. A., Selvaraj, E. A., Jayaswal, A. N. A., Trauner, M., Boursier, J., Fournier, C., Staufer, K., Stauber, R. E., Bugianesi, E., Younes, R., Gaia, S., Lupsor-Platon, M., Petta, S., Shima, T., Okanoue, T., Mahadeva, S., Chan, W. -K., Eddowes, P. J., Newsome, P. N., Wong, V. W. -S., de Ledinghen, V., Fan, J., Shen, F., Cobbold, J. F., Sumida, Y., Okajima, A., Schattenberg, J. M., Labenz, C., Kim, W., Lee, M. S., Wiegand, J., Karlas, T., Yilmaz, Y., Aithal, G. P., Palaniyappan, N., Cassinotto, C., Aggarwal, S., Garg, H., Ooi, G. J., Nakajima, A., Yoneda, M., Ziol, M., Barget, N., Geier, A., Tuthill, T., Brosnan, M. J., Anstee, Q. M., Neubauer, S., Harrison, S. A., Bossuyt, P. M., Pavlides, M., Anstee, Q., Daly, A., Johnson, K., Govaere, O., Cockell, S., Tiniakos, D., Bedossa, P., Oakley, F., Cordell, H., Day, C., Wonders, K., Bossuyt, P., Zafarmand, H., Vali, Y., Lee, J., Ratziu, V., Clement, K., Pais, R., Schuppan, D., Schattenberg, J., Vidal-Puig, T., Vacca, M., Rodrigues-Cuenca, S., Allison, M., Kamzolas, I., Petsalaki, E., Oresic, M., Hyotylainen, T., Mcglinchey, A., Mato, J. M., Millet, O., Dufour, J. -F., Berzigotti, A., Harrison, S., Cobbold, J., Mozes, F., Akhtar, S., Banerjee, R., Kelly, M., Shumbayawonda, E., Dennis, A., Erpicum, C., Graham, M., Romero-Gomez, M., Gomez-Gonzalez, E., Ampuero, J., Castell, J., Gallego-Duran, R., Fernandez, I., Montero-Vallejo, R., Karsdal, M., Erhardtsen, E., Rasmussen, D., Leeming, D. J., Fisker, M. J., Sinisi, A., Musa, K., Betsou, F., Sandt, E., Tonini, M., Rosso, C., Armandi, A., Marra, F., Gastaldelli, A., Svegliati, G., Francque, S., Vonghia, L., Ekstedt, M., Kechagias, S., Yki-Jarvinen, H., Porthan, K., van Mil, S., Papatheodoridis, G., Cortez-Pinto, H., Valenti, L., Miele, L., Trautwein, C., Aithal, G., Hockings, P., Newsome, P., Wenn, D., Rodrigues, C. M. P., Chaumat, P., Hanf, R., Trylesinski, A., Ortiz, P., Duffin, K., Brosnan, J., Mcleod, E., Ertle, J., Ostroff, R., Alexander, L., Kjaer, M. S., Mikkelsen, L. F., Balp, M. -M., Brass, C., Jennings, L., Martic, M., Loeffler, J., Hanauer, G., Shankar, S., Pepin, K., Ehman, R., Myers, J., Ho, G., Torstenson, R., Myers, R., Doward, L., LITMUS Investigators, University of Denver, Medizinische Universität Wien = Medical University of Vienna, Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques (HIFIH), Université d'Angers (UA), SUACI Alpes du Nord, Medical University Graz, Mozes, Ferenc Emil, Lee, Jenny A., Selvaraj, Emmanuel Anandraj, Jayaswal, Arjun Narayan Ajmer, Trauner, Michael, Boursier, Jerome, Fournier, Celine, Staufer, Katharina, Stauber, Rudolf E., Bugianesi, Elisabetta, Younes, Ramy, Gaia, Silvia, Lupsor-Platon, Monica, Petta, Salvatore, Shima, Toshihide, Okanoue, Takeshi, Mahadeva, Sanjiv, Chan, Wah-Kheong, Eddowes, Peter J., Hirschfield, Gideon M., Newsome, Philip Noel, Wong, Vincent Wai-Sun, de Ledinghen, Victor, Fan, Jiangao, Shen, Feng, Cobbold, Jeremy F., Sumida, Yoshio, Okajima, Akira, Schattenberg, Joern M., Labenz, Christian, Kim, Won, Lee, Myoung Seok, Wiegand, Johannes, Karlas, Thomas, Yilmaz, Yusuf, Aithal, Guruprasad Padur, Palaniyappan, Naaventhan, Cassinotto, Christophe, Aggarwal, Sandeep, Garg, Harshit, Ooi, Geraldine J., Nakajima, Atsushi, Yoneda, Masato, Ziol, Marianne, Barget, Nathalie, Geier, Andreas, Tuthill, Theresa, Brosnan, M. Julia, Anstee, Quentin Mark, Neubauer, Stefan, Harrison, Stephen A., Bossuyt, Patrick M., Pavlides, Michael, Epidemiology and Data Science, APH - Methodology, APH - Personalized Medicine, ACS - Atherosclerosis & ischemic syndromes, APH - Aging & Later Life, ARD - Amsterdam Reproduction and Development, Graduate School, Mozes F.E., Lee J.A., Selvaraj E.A., Jayaswal A.N.A., Trauner M., Boursier J., Fournier C., Staufer K., Stauber R.E., Bugianesi E., Younes R., Gaia S., Lupsor-Platon M., Petta S., Shima T., Okanoue T., Mahadeva S., Chan W.-K., Eddowes P.J., Newsome P.N., Wong V.W.-S., de Ledinghen V., Fan J., Shen F., Cobbold J.F., Sumida Y., Okajima A., Schattenberg J.M., Labenz C., Kim W., Lee M.S., Wiegand J., Karlas T., Yilmaz Y., Aithal G.P., Palaniyappan N., Cassinotto C., Aggarwal S., Garg H., Ooi G.J., Nakajima A., Yoneda M., Ziol M., Barget N., Geier A., Tuthill T., Brosnan M.J., Anstee Q.M., Neubauer S., Harrison S.A., Bossuyt P.M., Pavlides M., Anstee Q., Daly A., Johnson K., Govaere O., Cockell S., Tiniakos D., Bedossa P., Oakley F., Cordell H., Day C., Wonders K., Bossuyt P., Zafarmand H., Vali Y., Lee J., Ratziu V., Clement K., Pais R., Schuppan D., Schattenberg J., Vidal-Puig T., Vacca M., Rodrigues-Cuenca S., Allison M., Kamzolas I., Petsalaki E., Oresic M., Hyotylainen T., McGlinchey A., Mato J.M., Millet O., Dufour J.-F., Berzigotti A., Harrison S., Cobbold J., Mozes F., Akhtar S., Banerjee R., Kelly M., Shumbayawonda E., Dennis A., Erpicum C., Graham M., Romero-Gomez M., Gomez-Gonzalez E., Ampuero J., Castell J., Gallego-Duran R., Fernandez I., Montero-Vallejo R., Karsdal M., Erhardtsen E., Rasmussen D., Leeming D.J., Fisker M.J., Sinisi A., Musa K., Betsou F., Sandt E., Tonini M., Rosso C., Armandi A., Marra F., Gastaldelli A., Svegliati G., Francque S., Vonghia L., Ekstedt M., Kechagias S., Yki-Jarvinen H., Porthan K., van Mil S., Papatheodoridis G., Cortez-Pinto H., Valenti L., Miele L., Trautwein C., Aithal G., Hockings P., Newsome P., Wenn D., Rodrigues C.M.P., Chaumat P., Hanf R., Trylesinski A., Ortiz P., Duffin K., Brosnan J., McLeod E., Ertle J., Ostroff R., Alexander L., Kjaer M.S., Mikkelsen L.F., Balp M.-M., Brass C., Jennings L., Martic M., Loeffler J., Hanauer G., Shankar S., Pepin K., Ehman R., Myers J., Ho G., Torstenson R., Myers R., and Doward L.

Subjects
Liver Cirrhosis, Male, Cirrhosis, LIVER STIFFNESS MEASUREMENT, Biopsy, [SDV]Life Sciences [q-bio], biostatistics, Gastroenterology, DISEASE, clinical decision making, fatty liver, hepatic fibrosis, 0302 clinical medicine, Non-alcoholic Fatty Liver Disease, Fibrosis, 2. Zero hunger, 0303 health sciences, medicine.diagnostic_test, NONALCOHOLIC STEATOHEPATITIS, TRANSIENT ELASTOGRAPHY, Fatty liver, CHRONIC HEPATITIS, Middle Aged, 3. Good health, Settore AGR/03 - Arboricoltura Generale E Coltivazioni Arboree, Liver, Liver biopsy, BIOPSY, Elasticity Imaging Techniques, Female, 030211 gastroenterology & hepatology, Median body, medicine.medical_specialty, CONTROLLED ATTENUATION PARAMETER, 610 Medicine & health, 03 medical and health sciences, Internal medicine, SCORE, medicine, Humans, biostatistics, clinical decision making, fatty liver, hepatic fibrosis, 030304 developmental biology, Receiver operating characteristic, business.industry, medicine.disease, Diabetes Mellitus, Type 2, XL PROBE, business, Hepatic fibrosis, Transient elastography, Biomarkers, PROSPECTIVE DERIVATION
Abstract

ObjectiveLiver biopsy is still needed for fibrosis staging in many patients with non-alcoholic fatty liver disease. The aims of this study were to evaluate the individual diagnostic performance of liver stiffness measurement by vibration controlled transient elastography (LSM-VCTE), Fibrosis-4 Index (FIB-4) and NAFLD (non-alcoholic fatty liver disease) Fibrosis Score (NFS) and to derive diagnostic strategies that could reduce the need for liver biopsies.DesignIndividual patient data meta-analysis of studies evaluating LSM-VCTE against liver histology was conducted. FIB-4 and NFS were computed where possible. Sensitivity, specificity and area under the receiver operating curve (AUROC) were calculated. Biomarkers were assessed individually and in sequential combinations.ResultsData were included from 37 primary studies (n=5735; 45% women; median age: 54 years; median body mass index: 30 kg/m2; 33% had type 2 diabetes; 30% had advanced fibrosis). AUROCs of individual LSM-VCTE, FIB-4 and NFS for advanced fibrosis were 0.85, 0.76 and 0.73. Sequential combination of FIB-4 cut-offs (ConclusionSequential combinations of markers with a lower cut-off to rule-out advanced fibrosis and a higher cut-off to rule-in cirrhosis can reduce the need for liver biopsies.

Published
2022
Full Text
View/download PDF

4. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: An individual patient data meta-analysis

Author

Mózes, F.E. Lee, J.A. Selvaraj, E.A. Jayaswal, A.N.A. Trauner, M. Boursier, J. Fournier, C. Staufer, K. Stauber, R.E. Bugianesi, E. Younes, R. Gaia, S. Lupșor-Platon, M. Petta, S. Shima, T. Okanoue, T. Mahadeva, S. Chan, W.-K. Eddowes, P.J. Newsome, P.N. Wong, V.W.-S. de Ledinghen, V. Fan, J. Shen, F. Cobbold, J.F. Sumida, Y. Okajima, A. Schattenberg, J.M. Labenz, C. Kim, W. Lee, M.S. Wiegand, J. Karlas, T. Yılmaz, Y. Aithal, G.P. Palaniyappan, N. Cassinotto, C. Aggarwal, S. Garg, H. Ooi, G.J. Nakajima, A. Yoneda, M. Ziol, M. Barget, N. Geier, A. Tuthill, T. Brosnan, M.J. Anstee, Q.M. Neubauer, S. Harrison, S.A. Bossuyt, P.M. Pavlides, M. Anstee, Q. Daly, A. Johnson, K. Govaere, O. Cockell, S. Tiniakos, D. Bedossa, P. Oakley, F. Cordell, H. Day, C. Wonders, K. Bossuyt, P. Zafarmand, H. Vali, Y. Lee, J. Ratziu, V. Clement, K. Pais, R. Schuppan, D. Schattenberg, J. Schuppan, D. Schattenberg, J. Vidal-Puig, T. Vacca, M. Rodrigues-Cuenca, S. Allison, M. Kamzolas, I. Petsalaki, E. Oresic, M. Hyötyläinen, T. McGlinchey, A. Mato, J.M. Millet, O. Dufour, J.-F. Berzigotti, A. Pavlides, M. Harrison, S. Neubauer, S. Cobbold, J. Mozes, F. Akhtar, S. Banerjee, R. Kelly, M. Shumbayawonda, E. Dennis, A. Erpicum, C. Graham, M. Romero-Gómez, M. Gómez-González, E. Ampuero, J. Castell, J. Gallego-Durán, R. Fernández, I. Montero-Vallejo, R. Karsdal, M. Erhardtsen, E. Rasmussen, D. Leeming, D.J. Fisker, M.J. Sinisi, A. Musa, K. Betsou, F. Sandt, E. Tonini, M. Bugianesi, E. Rosso, C. Armandi, A. Marra, F. Gastaldelli, A. Svegliati, G. Boursier, J. Francque, S. Vonghia, L. Ekstedt, M. Kechagias, S. Yki-Jarvinen, H. Porthan, K. van Mil, S. Papatheodoridis, G. Cortez-Pinto, H. Valenti, L. Petta, S. Miele, L. Geier, A. Trautwein, C. Aithal, G. Hockings, P. Newsome, P. Wenn, D. Rodrigues, C.M.P. Chaumat, P. Hanf, R. Trylesinski, A. Ortiz, P. Duffin, K. Brosnan, J. Tuthill, T. McLeod, E. Ertle, J. Younes, R. Ostroff, R. Alexander, L. Kjær, M.S. Mikkelsen, L.F. Balp, M.-M. Brass, C. Jennings, L. Martic, M. Loeffler, J. Hanauer, G. Shankar, S. Fournier, C. Pepin, K. Ehman, R. Myers, J. Ho, G. Torstenson, R. Myers, R. Doward, L. LITMUS Investigators

Abstract

Objective Liver biopsy is still needed for fibrosis staging in many patients with non-alcoholic fatty liver disease. The aims of this study were to evaluate the individual diagnostic performance of liver stiffness measurement by vibration controlled transient elastography (LSM-VCTE), Fibrosis-4 Index (FIB-4) and NAFLD (non-alcoholic fatty liver disease) Fibrosis Score (NFS) and to derive diagnostic strategies that could reduce the need for liver biopsies. Design Individual patient data meta-analysis of studies evaluating LSM-VCTE against liver histology was conducted. FIB-4 and NFS were computed where possible. Sensitivity, specificity and area under the receiver operating curve (AUROC) were calculated. Biomarkers were assessed individually and in sequential combinations. Results Data were included from 37 primary studies (n=5735; 45% women; median age: 54 years; median body mass index: 30 kg/m2; 33% had type 2 diabetes; 30% had advanced fibrosis). AUROCs of individual LSM-VCTE, FIB-4 and NFS for advanced fibrosis were 0.85, 0.76 and 0.73. Sequential combination of FIB-4 cut-offs (

Published
2021

27. Abstracts of selected papers presented at the 30th Annual Meeting of the Japanese Society of Gastroenterology October 20–22, 1988 — Kagoshima, Japan

Author

Oda, Ichiro, Ogawa, Kaoru, Okada, Shuichi, Ueno, Keiichi, Itoh, Tohru, Horiguchi, Yuji, Kijima, Hiroshi, Inui, Kazuo, Koga, Akitoshi, Hamamoto, Tetsuro, Tsukada, Hideaki, Tamada, Takashi, Nakamura, Takahiko, Okanoue, T., Koike, Daisuke, Abe, Hirohiko, Miura, Tsutomu, Hashimoto, Shuji, Oda, M., Azuma, T., Nagata, Shigeyuki, Ishii, Hiromasa, Kawada, Norifumi, Mizoguchi, Yasuhiro, Yoshikawa, Yuji, Oka, Hiroshi, Ichida, Takafumi, Ichida, Fumihiro, Ueno, Takato, Tanikawa, Kyuichi, Kokudo, Norihiro, Kawasaki, Seiji, Onji, Morikazu, Miyaoka, Hiroaki, Yokosuka, Osamu, Omata, Masao, Ikeda, Hiroshi, Tsuji, Takao, Hayashi, Shigeki, Fujiwara, Kenji, Yasunaga, Mitsuru, Okita, Kiwamu, Takase, Koujirou, Tameda, Yukihiko, Ohnishi, Hiroo, Sugihara, Jun-ichi, Kojima, Hideo, Kamimura, Tomoteru, Tanaka, Eiji, Yoda, Hidetoshi, Kanno, Atsushi, Ohtsuki, Masao, Miyata, Yasuji, Koga, Shunichi, Unoura, Masashi, Tanaka, Nobuyoshi, Kodama, Takahiro, Nishimura, Hideo, Suzuki, Kazuyuki, Madarame, Takeo, Komatsu, Masafumi, Ookubo, Shunji, Nishiyama, Masataka, Saito, Shozo, Kumashiro, Ryukichi, Tanikawa, Kyuichi, Ikeda, Kenji, Kumada, Hiromitsu, Nishiguchi, Shuhei, Kuroki, Tetsuo, Yoshiba, Makoto, Takeuchi, Yukari, Morito, Takao, Kasukawa, Reiji, Takeda, Isao, Nakano, Satoshi, Matsumura, Kenzo, Imanari, Tomohiro, Lee, Shigeki, Fujita, Naotaka, Mine, Tetsuya, Sato, Eiichi, Suyama, Masafumi, Ariyama, Jo, Takahashi, Toshihisa, Hirano, Masanori, Hirai, Atsushi, Yamakawa, Tatsuo, Kamiya, Junichi, Nimura, Yuji, Yoshimoto, Hideo, Ikeda, Seiyo, Yamasuji, Tadashi, Saeki, Keizo, Itoh, Masaki, Kajiyama, Goro, Seki, Hideichi, Kimura, Ken, Nakamura, Hiroshi, Tsuchiya, Yukihiro, Omura, Ryosuke, Tanaka, Shinya, Shimakura, Katsuhide, Matsuda, Yoshiaki, Wakabayashi, Tokio, Morimoto, Hideo, Kamiya, Yasutaka, Okayama, Yasutaka, Kobayashl, Masao, Fujimoto, Sotaro, Yamaguchi, Atsumasa, Shibue, Tadashi, Akashi, Ryukichi, Hattori, Masahiro, Takehira, Yasunori, Tsugane, Yasutoshi, Tashiro, Yoshinori, Kuwayama, Hajime, Kon, Yoichi, Higuchi, Tsugio, Hirata, Nobuto, Kano, Tomoyuki, Kurimoto, Kumiko, Kubota, Y., Seki, T., Kamura, Yoshimine, Nakayama, Toshimichi, Yoshimura, Hitoshi, Yoshioka, Tetsuya, Akimoto, Kimihiko, Mine, Tetsuya, Sato, Eiichi, Ohnishi, Hirohide, Ogata, Etsuro, Igarashi, Atsushi, Kadowaki, Atsushi, Yaoita, Tsutomu, Sato, Naoki, Monma, Kimitsune, Kogure, Hiroaki, Tajima, Yoshio, Takanashi, Hideki, Tsuchiya, Yukihiro, Haniya, Kazuo, Ohto, Masao, Murata, Ikuo, Tanaka, Takashi, Sakabe, Takashi, Kato, Takashi, Koike, Tadashi, Watanabe, Tetsuya, Nakamura, Tetsuo, Kato, H., Ikai, I., Nishimura, N., Kobayashi, N., Ozawa, K., Ono, Katsuyuki, Sata, Michio, Abe, Hirohiko, Tanikawa, Kyuichi, Kadowaki, Ken, Ikoma, Jiro, Kojima, Yuji, Murata, Tetsuya, Kakehashi, Ryuichi, Ibe, Toshio, Kano, Uichiro, Ito, Tetsuo, Tanaka, Takeshi, Watanabe, Shozo, Suzuki, Shiro, Nakazawa, Osamu, Kohda, Kyuhei, Ohyama, Kohzo, Terada, Shoki, Sazaki, Katsuhiko, Kure, Teikichi, Morita, Koetsu, Shida, Osamu, Muramatsu, Hiroshi, Niitsu, Yoshiro, Tozuka, Shinichi, Sakai, Yoshinori, Ikeda, Takaaki, Koyama, Wataru, Sakamoto, Shigemi, Kanayama, Masaaki, Tanaka, Naohide, Arakawa, Yasuyuki, Matsuo, Yutaka, Takaguchi, Kouichi, Yamada, Gotaro, Matsuura, Kazuharu, Ikeda, Hirosi, Iwasaki, Yoshiaki, Nouso, Kazuhiro, Matsueda, Kazuhiro, Sawahara, Masahiko, Fujiki, Shigeatsu, Mizuno, Motowo, Yama, Shingo Kino, Tsuji, Takao, Nadano, Seijin, Horiike, Norio, Michitaka, Kojiro, Kumon, Izumi, Ogawa, Yasushi, Yamaguchi, Shuji, Onji, Morikazu, Ohta, Yasuyuki, Nishi, Masaaki, Matsuzaki, Yasushi, Tanaka, Naomi, Matsumoto, Hisashi, Chuganji, Yoshimichi, Osuga, Toshiaki, Shoji, S., Kurata, M., Wakashima, M., Itoh, Y., Hagiri, M., Kondou, T., Katayama, M., Nishizawa, K., Takikawa, H., Ohsawa, H., Miyake, M., Yamanaka, M., Ooka, Teruji, Akita, Masahiko, Kim, Hogen, Kato, Michio, Masuzawa, Manabu, Okuyama, Takumasa, Akiyama, Masahiko, Ishigami, Yoshitaka, Tamura, Kazuya, Fukui, Osamu, Abe, Hiroshi, Kamada, Takenobu, Arai, Ken, Shindo, Michiko, Okuno, Tadao, Matsumoto, Masayuki, Takeda, Makoto, Takino, Tatsuro, Sokawa, Yoshihiro, Omata, M., Yokosuka, O., Ito, Y., Hosoda, K., Ohto, M., Fuse, Yoshinobu, Kodama, Tadashi, Sugiyama, Kenji, Nakajo, Shinobu, Ajitsu, Shin, Takahashi, Tsuneo, Kuroe, K., Murata, Y., Ikeda, Hideo, and Tanikawa, Kyuichi

Published
1990
Full Text
View/download PDF

36. Algorithms using noninvasive tests can accurately identify patients with advanced fibrosis due to NASH: data from the STELLAR clinical trials

Author

Lampertico, P., primary, Younossi, Z.M., additional, Lawitz, E.J., additional, Alkhouri, N., additional, Wong, V. Wai-Sun, additional, Romero-Gomez, M., additional, Okanoue, T., additional, Trauner, M., additional, Kersey, K., additional, Li, G., additional, Subramanian, G.M., additional, Myers, R.P., additional, Djedjos, C.S., additional, Han, L., additional, Chen, G., additional, Nguyen, T., additional, Kohli, A., additional, Bzowej, N., additional, Younes, Z., additional, Sarin, S., additional, Shiffman, M.L., additional, Harrison, S.A., additional, Goodman, Z., additional, Afdhal, N.H., additional, Stepanova, M., additional, and Anstee, Q.M., additional

Published
2019
Full Text
View/download PDF

41. Measurement of hepatitis B virus core-related antigen is valuable for identifying patients who are at low risk of lamivudine resistance

Author

Tanaka, E; HFDCHekh, Matsumoto, A, Suzuki, F, Kobayashi, M, Mizokami, M, Tanaka, Y, Okanoue, T, Minami, M, Chayama, K, Imamura, M, Yatsuhashi, H, Nagaoka, S, Yotsuyanagi, H, Kawata, S, Kimura, T, Maki, N, Iino, S, Kiyosawa, K, Tanaka, E; HFDCHekh, Matsumoto, A, Suzuki, F, Kobayashi, M, Mizokami, M, Tanaka, Y, Okanoue, T, Minami, M, Chayama, K, Imamura, M, Yatsuhashi, H, Nagaoka, S, Yotsuyanagi, H, Kawata, S, Kimura, T, Maki, N, Iino, S, and Kiyosawa, K

Published
2007

43. Obstructive jaundice with fever and eosinophilia

Author

Inoue, K., primary, Kanemasa, H., additional, Inoue, K., additional, Matsumoto, M., additional, Kajita, Y., additional, Mitsufuji, S., additional, Kataoka, K., additional, Okanoue, T., additional, Yamada, M., additional, Uchikawa, R., additional, Tegoshi, T., additional, and Arizono, N., additional

Published
2009
Full Text
View/download PDF

46. Obstructive jaundice with fever and eosinophilia

Author

Inoue, K., primary, Kanemasa, H., additional, Inoue, K., additional, Matsumoto, M., additional, Kajita, Y., additional, Mitsufuji, S., additional, Kataoka, K., additional, Okanoue, T., additional, Yamada, M., additional, Uchikawa, R., additional, Tegoshi, T., additional, and Arizono, N., additional

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results